CD8A and neoplasm: The recombinant CMV virus could be used as a prophylactic or therapeutic tumor vaccine vector, and vaccination of this SIINFEKL epitope expressing RAE-1γ MCMV was able to induce SIINFEKL-specific CD8+ T cells and provide long-term protection to delay or prevent the growth of melanoma cells expressing ovalbumin [67].